ELVN vs. TYRA, TNGX, PLRX, ARCT, ALXO, AUPH, IRON, NRIX, SVRA, and OPK
Should you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Tyra Biosciences (TYRA), Tango Therapeutics (TNGX), Pliant Therapeutics (PLRX), Arcturus Therapeutics (ARCT), ALX Oncology (ALXO), Aurinia Pharmaceuticals (AUPH), Disc Medicine (IRON), Nurix Therapeutics (NRIX), Savara (SVRA), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Tyra Biosciences (NASDAQ:TYRA) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 18.4% of Tyra Biosciences shares are owned by company insiders. Comparatively, 45.8% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Tyra Biosciences presently has a consensus price target of $22.00, suggesting a potential upside of 41.57%. Enliven Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 104.20%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Tyra Biosciences.
Tyra Biosciences has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.
In the previous week, Enliven Therapeutics had 4 more articles in the media than Tyra Biosciences. MarketBeat recorded 5 mentions for Enliven Therapeutics and 1 mentions for Tyra Biosciences. Enliven Therapeutics' average media sentiment score of 0.59 beat Tyra Biosciences' score of 0.23 indicating that Tyra Biosciences is being referred to more favorably in the media.
Tyra Biosciences received 11 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 57.69% of users gave Tyra Biosciences an outperform vote.
Tyra Biosciences is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences' return on equity of -26.56% beat Enliven Therapeutics' return on equity.
Summary
Enliven Therapeutics beats Tyra Biosciences on 9 of the 15 factors compared between the two stocks.
Get Enliven Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enliven Therapeutics Competitors List
Related Companies and Tools
